European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted.

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

MedCity News

OCTOBER 20, 2024

Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News.

Pharma 123

Pharma Leads Pharmaceutical Biopharma 123

MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 105

Leads Pharma Pharmaceutical Patients 105

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA).

Biopharma 311

Biopharma Leads 311

Pharmaceutical Commerce

SEPTEMBER 6, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Distribution 52

Distribution Biopharma Leads Healthcare 52

Pharmaceutical Technology

SEPTEMBER 8, 2022

The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness. Discover the top speciality pharmacies.

Specialization 45

Specialization Leads Pharma Side effects 45

European Pharmaceutical Review

AUGUST 24, 2023

This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. Venture funding in 2022 came in at about $13.7 billion, down from the high of 2021.

Biopharma 98

Biopharma Pharmaceutical Pharma Medical 98

European Pharmaceutical Review

NOVEMBER 16, 2022

For young biotechs, scaling up production brings green-field challenges, while for more established pharma a shift may be required to ensure that facilities are optimised for new ways of working. So what might that look like? Making quality more integral to production. Embracing the spirit rather than the letter of regulations.

Manufacturing 119

Manufacturing Pharma Biopharma Management 119

MedCity News

SEPTEMBER 23, 2022

Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure.

Leads 113

Leads Pharma Pharmaceutical Biopharma 113

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

MedCity News

APRIL 10, 2024

The lead indication for the Alpine drug, povetacicept, is the chronic kidney disease IgA nephropathy. The post Vertex Pharma Bolsters Immunology Profile With $4.9B Vertex Pharmaceuticals gains a Phase 3-ready Alpine Immune Sciences drug with potential applications in a wide range of immunological disorders.

Pharma 101

Pharma Pharmaceutical Leads Biopharma 101

Pharmaceutical Technology

MAY 15, 2023

Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively. Exelixis is a biopharmaceutical company that focuses on the development and commercialisation of small molecules for the treatment of cancer. By means of geographic reach, Cytokinetics holds the top position.

Leads 92

Leads Biopharma Pharmaceutical Pharma 92

MedCity News

OCTOBER 29, 2024

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million.

Biopharma 107

Biopharma Leads Pharma 107

MedCity News

APRIL 30, 2024

Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P.

Leads 121

Leads Safety Biopharma Pharma 121

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma 113

Biopharma Leads Pharma 113

European Pharmaceutical Review

AUGUST 9, 2022

After a prolonged period of scepticism towards major moves in the mergers and acquisitions (M&A) market, leading biopharmaceutical multinationals are returning to big deal-making. In addition, and quite significantly, it was “Big Pharma” that was largely responsible for this uptick.

Pharma 69

Pharma Biopharma Leads Specialization 69

MedCity News

MAY 6, 2024

Novo-Catalent Deal, Leading to Another Delay appeared first on MedCity News. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process. The post FTC Seeks More Information on the $16.5B

Leads 114

Leads Management Biopharma Pharma 114

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma 114

Biopharma Leads Pharma 114

PM360

OCTOBER 8, 2024

A serial entrepreneur, executive business leader and board member, he brings more than 35 years’ experience of critical safety service and technology solution provision to biopharma R&D, Commercial and Operations functions. It was a great honor to be approached to lead Qinecsa’s next important growth phase.

Leads 52

Leads Safety Biopharma Management 52

MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 110

Leads FDA Biopharma Pharma 110

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 on 6 th January.

Pharma 98

Pharma Biopharma Management Medicine 98

Pharmaceutical Technology

MAY 15, 2023

11 Unlock company profile Strides Pharma Science 11 Unlock company profile Sumitomo Chemical 11 Unlock company profile Eli Lilly and 9 Unlock company profile Araxes Pharma 9 Unlock company profile North & South Brother Pharmacy Investment 9 Unlock company profile Source: GlobalData Patent Analytics F.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

Pharmaceutical Technology

MAY 15, 2023

In terms of application diversity, Ascentawits Pharmaceuticals is the top company, followed by OBI Pharma and Mabwell Shanghai Bioscience. Besides Seagen, Takeda Pharmaceutical and Immatics are the other key patent filers of peptide-based inhibitors for the treatment of cancer. By means of geographic reach, Onxeo holds the top position.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

MedCity News

NOVEMBER 4, 2024

The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals.

Pharma 106

Pharma FDA Leads Biopharma 106

Pharmaceutical Technology

MARCH 14, 2023

The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment.

Leads 72

Leads Biopharma Pharmaceutical Manufacturing 72

MedCity News

JANUARY 19, 2023

Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.

Pharma 100

Pharma Pharmaceutical Leads Biopharma 100

pharmaphorum

DECEMBER 18, 2022

Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. However, the cumbersome hub workflow overshadows the purported gains in productivity.

Biopharma 98

Biopharma Patients Prescription Medical 98

Pharmaceutical Technology

JUNE 4, 2023

Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders. The company’s drug ETX-101, comprising a recombinant adeno-associated virus (AAV9) vector, is under development for the treatment of Dravet syndrome.

Pharmaceutical 105

Pharmaceutical Leads Biopharma Engineering 105

PM360

NOVEMBER 21, 2024

is a leading neuroscience-focused, biopharmaceutical company headquartered in San Diego, CA, with a single purpose: to relieve suffering for people with great needs but few options. Neurocrine Biosciences, Inc. Neurocrine Biosciences was founded in 1992 and has grown today to 1,436 U.S.-based

Pharma 52

Pharma Training Biopharma Manufacturing 52

Pharmaceutical Technology

MAY 24, 2023

Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Menarini Industrie Farmaceutiche Riunite. By means of geographic reach, Curis holds the top position.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

MedCity News

NOVEMBER 27, 2022

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads 110

Leads Biopharma Pharma 110

Pharmaceutical Technology

MAY 8, 2023

Hoffmann-La Roche is the leading patent filer in monoclonal antibody conjugates for cancer treatment. By means of geographic reach, Astellas Pharma holds the top position, while TRON and Eisai stand in second and third positions, respectively. Kadcyla, one of the two marketed drugs, is manufactured by Roche.

Leads 52

Leads Pharmaceutical Biopharma Pharma 52

pharmaphorum

DECEMBER 16, 2022

The Japanese pharma says it will now start talking to regulatory authorities around the world about potential marketing applications for zolbetuximab as a first-line treatment for patients with locally advanced unresectable or metastatic gastric and gastro-oesophageal (GEJ) cancer. Other companies developing claudin 18.2-targeted

Leads 59

Leads Biopharma Prospecting Patients 59

MedCity News

JANUARY 24, 2023

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

Leads 85

Leads Biopharma Pharma 85

PM360

SEPTEMBER 30, 2024

Sustainable Tech’s Positive Effect on Pharma Funding Recent innovations, including rapid advancements in AI-powered technologies and GLP-1s, have significantly impacted the investment climate and consolidated funding to a smaller number of organizations in the last eight months.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

MedCity News

MAY 2, 2024

Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space.

Pharma 118

Pharma Leads Biopharma 118